Childhood cancer is considered a rare disease that accounts for about 1% of all U.S. cancer diagnoses. Although pediatric cancer death rates have declined over the past four decades due to improved tumor detection and treatment, cancer is still the leading cause of death by disease among children in the U.S. Moreover, more than 95% of childhood cancer survivors will have significant health-related issues and an increased risk of future secondary sarcomas because of the cancer treatments administered, the vast majority designed and developed for adult indications.
“The mission of the Catalytic Impact Foundation (CIF) is to accelerate innovations in life sciences and healthcare, funding companies that address high unmet medical needs. The lack of treatments specifically designed and developed for children with cancer is astonishing, and CIF is delighted to support Oncoheroes’ innovative approach to tackling this urgent need,” announced Rachel Butler, CIF’s President.
CIF is supported by philanthropic donors with a passion to help early-stage health and life sciences companies that have the potential to have a significant impact in Women’s Health, Brain Health, Children’s Health, Aging, and Pediatric Rare Diseases, among other areas.
“We are grateful to the Catalytic Impact Foundation for their trust in Oncoheroes. In the past decade, the practice of venture philanthropy is increasingly being adopted by disease-focused foundations helping to accelerate the development of new therapies. We hope CIF’s approach will inspire more foundations, especially those who care about childhood cancer, to join our effort,” stated Ricardo Garcia, CEO of Oncoheroes Biosciences.
